Evidence map›Paper›PMID 23055021›Full record

ArticlePathology oncology research : POR2013

Selected immuno-histochemical markers in curettage specimens and their correlation with final pathologic findings in endometrial cancer patients.

Basil R Obeidat, Ismail I Matalka, Alia A Mohtaseb, Nabih S Al-Kaisi

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Basil R ObeidatDepartment of Obstetrics and Gynecology, Jordan University of Science and Technology, P.O. Box 2954, Irbid, 21110, Jordan. b_obeidat@hotmail.com
Ismail I Matalka
Alia A Mohtaseb
Nabih S Al-Kaisi
Jordan University of Science and Technology · JOKing Hussein Medical Center · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To assess the immuno-histochemical expression of various markers in, endometrial biopsies of patients with endometrial cancer, and to correlate their expression with the final pathologic findings. Sixty-two patients with primary endometrial cancer who underwent surgical treatment were included in this study. Immuno-histochemical expression of estrogen receptor (ER), progesterone receptor (PR), p53, bcl-2, Her-2/neu and Ki-67 were assessed in curettage specimens, and review of the final pathology report from hysterectomy specimens was carried out. The expression of these markers in curettage was correlated with the final tumor characteristics obtained on hysterectomy specimens. Both ER and PR were significantly more expressed in endometrioid type (EC) than non- endometrioid type (NEC) (P value of 0.004 and 0.012). On the contrary, P53, Her-2 and Ki-67 showed higher positivity in NEC than EC (P value of 0.005, 0.025 and 0.002). Positive expression of ER and PR was significantly associated with low grade tumors and superficial myometrial invasion, whereas positive expression of Her-2 and Ki-67 was significantly associated with higher grade lesions, and deep myometrial invasion. Moreover, a statistically significant inverse relationship was observed between the positivity of P53, Her-2 and Ki-67 and the positivity of ER, PR. We found that determination of immuno-histochemical markers in curettage specimens might be helpful in predicting the final pathologic findings in patients with endometrial cancer. This might be helpful in planning the extensivity of the surgery.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCurettageEndometrial NeoplasmsFemaleHumansImmunohistochemistryKi-67 AntigenMiddle AgedOncogene Proteins v-erbBProto-Oncogene Proteins c-bcl-2Receptors, EstrogenReceptors, ProgesteroneTumor Suppressor Protein p53Biomarkers, TumorKi-67 AntigenOncogene Proteins v-erbBProto-Oncogene Proteins c-bcl-2Receptors, EstrogenReceptors, ProgesteroneTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID23055021
OpenAlexW2084049072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.